TY - JOUR
T1 - Comparative chromatography-mass spectrometry studies on the antiretroviral drug nevirapine-Analytical performance characteristics in human plasma determination
AU - Sichilongo, Kwenga
AU - Chinyama, Mompati
AU - Massele, Amos
AU - Vento, Sandro
N1 - Funding Information:
The authors wish to thank the University of Botswana Office of Research and Development (ORD) for financial support. Others who offered financial/material assistance included Boehringer Ingelheim Pharma GmbH & Co., Germany. Mompati Chinyama thanks the University of Botswana Foundation (UB Foundation) for financial assistance toward his study. The authors also thank the University of Botswana, Faculty of Science and the Department of Chemistry for material support. Mr. Disang Mosimanethebe is also acknowledged for his technical assistance on this project.
PY - 2014/1/15
Y1 - 2014/1/15
N2 - A contrast between the analytical performance characteristics using gas chromatography-mass spectrometry (GC-MS) liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-ultraviolet (LC-UV) detection for the determination of the antiretroviral drug (ARV) nevirapine (NVP) in fortified human plasma after QuEChERS extraction has been made. Analytical performance characteristics, i.e. linearities, instrument detection limits (IDLs), limits of quantitation (LOQs), method detection limits (MDLs), % mean recoveries and the corresponding relative standard deviations (%RSDs) were estimated using techniques above. Using GC-MS, the correlation coefficients (r2) were ≥0.990, which were deemed acceptable linearities. The MDLs ranged between 11.1-29.8μg/L and 13.7-36.0μg/L using helium and hydrogen carrier gases respectively. The LOQs ranged between 16.5-66.7μg/L and 28.4-98.7μg/L using helium and hydrogen carrier gases respectively with a % mean recovery of 83% and %RSD of 4.6%. Using LC-MS and LC-UV, the correlation coefficients (r2) were ≥0.990. The MDLs were ranged between 3.14 and 47.1μg/L. The LOQs ranged between 2.85 and 90.0μg/L respectively. The MDLs using GC-MS, LC-MS and LC-UV were below the therapeutic range for NVP in human plasma is considered to be between 2300μg/L (Cmin) and 8000μg/L (Cmax). This study also demonstrated that helium can be substituted with hydrogen which is relatively cheaper and easily obtainable even by use of a generator.
AB - A contrast between the analytical performance characteristics using gas chromatography-mass spectrometry (GC-MS) liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-ultraviolet (LC-UV) detection for the determination of the antiretroviral drug (ARV) nevirapine (NVP) in fortified human plasma after QuEChERS extraction has been made. Analytical performance characteristics, i.e. linearities, instrument detection limits (IDLs), limits of quantitation (LOQs), method detection limits (MDLs), % mean recoveries and the corresponding relative standard deviations (%RSDs) were estimated using techniques above. Using GC-MS, the correlation coefficients (r2) were ≥0.990, which were deemed acceptable linearities. The MDLs ranged between 11.1-29.8μg/L and 13.7-36.0μg/L using helium and hydrogen carrier gases respectively. The LOQs ranged between 16.5-66.7μg/L and 28.4-98.7μg/L using helium and hydrogen carrier gases respectively with a % mean recovery of 83% and %RSD of 4.6%. Using LC-MS and LC-UV, the correlation coefficients (r2) were ≥0.990. The MDLs were ranged between 3.14 and 47.1μg/L. The LOQs ranged between 2.85 and 90.0μg/L respectively. The MDLs using GC-MS, LC-MS and LC-UV were below the therapeutic range for NVP in human plasma is considered to be between 2300μg/L (Cmin) and 8000μg/L (Cmax). This study also demonstrated that helium can be substituted with hydrogen which is relatively cheaper and easily obtainable even by use of a generator.
KW - GC-MS
KW - LC-MS
KW - LC-UV
KW - Nevirapine
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=84890026452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890026452&partnerID=8YFLogxK
U2 - 10.1016/j.jchromb.2013.11.046
DO - 10.1016/j.jchromb.2013.11.046
M3 - Article
C2 - 24325830
AN - SCOPUS:84890026452
VL - 945-946
SP - 101
EP - 109
JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
SN - 1570-0232
ER -